🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

HealthStream Announces First Quarter 2024 Results

Published 23-04-2024, 02:12 am
HSTM
-

NASHVILLE, Tenn.--(BUSINESS WIRE)--HealthStream, Inc. (the Company) (Nasdaq: HS™), a leading healthcare technology platform for workforce solutions, announced today results for the first quarter ended March 31, 2024.

First Quarter 2024

  • Revenues of $72.8 million in the first quarter of 2024, up 6% from $68.9 million in the first quarter of 2023
  • Operating income of $5.7 million in the first quarter of 2024, up 97% from $2.9 million in the first quarter of 2023
  • Net income of $5.2 million in the first quarter of 2024, up 99% from $2.6 million in the first quarter of 2023
  • Earnings per share (EPS) of $0.17 per share (diluted) in the first quarter of 2024, up from $0.09 per share (diluted) in the first quarter of 2023
  • Adjusted EBITDA1 of $17.1 million in the first quarter of 2024, up 24% from $13.7 million in the first quarter of 2023
  • Board of Directors declared a quarterly cash dividend of $0.028 per share, payable on May 17, 2024 to holders of record on May 6, 2024

1 Adjusted EBITDA is a non-GAAP financial measure. A reconciliation of adjusted EBITDA to net income and disclosure regarding why we believe adjusted EBITDA provides useful information to investors is included later in this release.

Financial Results:
First Quarter 2024 Compared to First Quarter 2023
Revenues for the first quarter of 2024 increased by $3.8 million, or six percent, to $72.8 million, compared to $68.9 million for the first quarter of 2023. Subscription revenues increased $4.2 million, or six percent, and professional services revenues declined by $0.4 million.

Operating income was $5.7 million for the first quarter of 2024, up 97 percent from $2.9 million in the first quarter of 2023. The improvement in operating income was primarily attributable to increased revenues, a reduction in labor costs (primarily resulting from $1.0 million of severance charges incurred during the first quarter of 2023 in connection with the Company's restructuring under a single platform strategy), a decrease in professional fees, and an increase in capitalized labor associated with software development activities, which were partially offset by increases in software, cloud hosting expenses, royalties, amortization, and general marketing expenses.

Net income was $5.2 million in the first quarter of 2024, up 99 percent from $2.6 million in the first quarter of 2023, and EPS was $0.17 per share (diluted) in the first quarter of 2024, up from $0.09 per share (diluted) in the first quarter of 2023. Net income and EPS for the first quarter of 2023 were negatively impacted by severance charges recognized in the amounts of $0.8 million and $0.03 per share (diluted), respectively, in connection with the 2023 restructuring discussed above.

Adjusted EBITDA was $17.1 million for the first quarter of 2024, up 24 percent from $13.7 million in the first quarter of 2023.

At March 31, 2024, the Company had cash and cash equivalents and marketable securities of $83.7 million. The Company does not have any outstanding indebtedness for borrowed money. Capital expenditures incurred during the first quarter of 2024 were $6.9 million.

Other Business Updates
On September 13, 2023, the Company announced a share repurchase program under which the Company was authorized to repurchase up to $10.0 million of its outstanding shares of common stock. Pursuant to this authorization, the Company repurchased shares valued at an aggregate of $8.9 million, with no shares repurchased during the three months ended March 31, 2024. The program expired on March 31, 2024.

On April 22, 2024, the Board approved a quarterly cash dividend under the Company's dividend policy of $0.028 per share, payable on May 17, 2024 to holders of record on May 6, 2024.

Financial Outlook for 2024
The Company reaffirms its guidance for 2024 for the measures set forth below as previously announced on February 19, 2024. For a reconciliation of projected adjusted EBITDA, a non-GAAP financial measure defined later in this release, to projected net income (the most comparable GAAP measure) for 2024, see the table included on page nine of this release.

 

Full-Year 2024 Guidance

 

 

Low

 

 

 

 

 

High

 

 

Revenue

 

$

292.0

 

 

-

 

 

$

296.0

 

million

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA1

 

$

64.5

 

 

-

 

 

$

67.5

 

million

 

 

 

 

 

 

 

 

 

 

 

 

 

Capital Expenditures

 

$

28.0

 

 

-

 

 

$

30.0

 

million

1 Adjusted EBITDA is a non-GAAP financial measure. A reconciliation of projected adjusted EBITDA to projected net income (the most comparable GAAP measure) is included later in this release.

The Company's guidance for 2024 as set forth above reflects the Company's assumptions regarding, among other things, expectations for new sales and renewals, and assumes that general economic conditions, including inflationary pressures, do not deteriorate. This consolidated guidance does not include the impact of any acquisitions that we may complete during 2024, gains or losses from changes in the fair value of minority investments, or impairment of long-lived assets.

Commenting on first quarter 2024 results, Robert A. Frist, Jr., Chief Executive Officer, HealthStream (NASDAQ:HSTM), said, We were pleased to achieve record quarterly revenues, record adjusted EBITDA, and a strong quarter overall, giving us confidence to reiterate our previously announced financial guidance. We believe our workforce solutions are well-aligned with the current industry focus to engage, retain, and develop the healthcare workforce.

A conference call with Robert A. Frist, Jr., Chief Executive Officer, Scott A. Roberts, Chief Financial Officer and Senior Vice President, and Mollie Condra, Vice President of Investor Relations and Corporate Communications, will be held on Tuesday, April 23, 2024, at 9:00 a.m. (ET). Participants may access the conference call live via webcast using this link: https://edge.media-server.com/mmc/p/qb8uq3o7. To participate via telephone, please register in advance using this link: https://register.vevent.com/register/BI99e7a8ec23464d6b8234f2b518bc2799. A replay of the conference call and webcast will be archived on the Company's website in the Investor Relations section under Events & Presentations.

Use of Non-GAAP Financial Measures
This press release presents adjusted EBITDA, a non-GAAP financial measure used by management in analyzing the Company's financial results and ongoing operational performance. In order to better assess the Company's financial results, management believes that net income before interest, income taxes, stock-based compensation, depreciation and amortization, and changes in fair value of, including gains (losses) on the sale of, non-marketable equity investments (adjusted EBITDA), is a useful measure for evaluating the operating performance of the Company because adjusted EBITDA reflects net income adjusted for certain GAAP accounting, non-cash, and/or non-operating items which may not, in any such case, fully reflect the underlying operating performance of our business. In addition, as discussed below, for periods ended on or prior to December 31, 2023, adjusted EBITDA excludes the impact of the deferred revenue write-downs associated with fair value accounting for acquired businesses. We believe that adjusted EBITDA is useful to investors to assess the Company's ongoing operating performance and to compare the Company's operating performance between periods. In addition, certain short-term cash incentive bonuses and performance-based equity awards are based on the achievement of adjusted EBITDA (as defined in applicable bonus and equity grant documentation) targets.

As previously disclosed, prior to the Company early adopting ASU 2021-08 effective January 1, 2022, following the completion of any acquisition by the Company, the Company was required to record the acquired deferred revenue at fair value as defined in GAAP, which typically resulted in a write-down of the acquired deferred revenue. In connection therewith, management determined that including an adjustment in the definition of adjusted EBITDA for the impact of the deferred write-downs associated with fair value accounting for businesses acquired prior to the January 1, 2022 effective date of the Company's adoption of ASU 2021-08 (the Pre-2022 Acquisitions) provided useful information to investors because the deferred revenue write-down recognized in periods after any such Pre-2022 Acquisitions could, given the nature of this non-cash accounting impact, cause our GAAP financial results during such periods to not fully reflect our underlying operating performance. Following the adoption of ASU 2021-08, contracts acquired in an acquisition completed on or after January 1, 2022 have been measured as if the Company had originated the contract (rather than the contract being measured at fair value) such that, for such acquisitions, the Company no longer records deferred revenue write-downs associated with acquired businesses. With respect to periods ended on or prior to December 31, 2023, the Company has included an adjustment in the calculation of adjusted EBITDA for the impact of deferred revenue write-downs associated with the Pre-2022 Acquisitions consistent with this prior accounting standard, given the ongoing impact of such deferred revenue on our financial results under GAAP over this time period. With respect to periods beginning on and after January 1, 2024, the Company is no longer recognizing any deferred revenue write-downs associated with the Pre-2022 Acquisitions under GAAP, and accordingly such deferred revenue write-downs are no longer an adjustment in connection with the calculation of adjusted EBITDA for periods beginning on and after January 1, 2024.

Adjusted EBITDA is a non-GAAP financial measure and should not be considered as a measure of financial performance under GAAP. Because adjusted EBITDA is not a measurement determined in accordance with GAAP, adjusted EBITDA is susceptible to varying calculations. Accordingly, adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies and has limitations as an analytical tool.

This non-GAAP financial measure should not be considered a substitute for, or superior to, measures of financial performance, which are prepared in accordance with GAAP. Investors are encouraged to review the reconciliations of adjusted EBITDA to net income (the most comparable GAAP measure), which is set forth below in this release.

About HealthStream
HealthStream (Nasdaq: HS™) is the healthcare industry's largest ecosystem of platform-delivered workforce solutions that empowers healthcare professionals to do what they do best: deliver excellence in patient care. For more information about HealthStream, visit www.healthstream.com or call 800-521-0574.

HEALTHSTREAM, INC.

Condensed Consolidated Statements of Income

(In thousands, except per share data)

(Unaudited)

 

 

 

 

 

Three Months Ended

 

 

March 31, 2024

 

 

March 31, 2023

Revenues, net

 

$

72,760

 

 

$

68,946

Operating costs and expenses:

 

 

 

 

 

 

 

Cost of revenues (excluding depreciation and amortization)

 

 

24,617

 

 

 

23,856

Product development

 

 

12,032

 

 

 

11,680

Sales and marketing

 

 

11,773

 

 

 

11,728

Other general and administrative expenses

 

 

8,312

 

 

 

8,865

Depreciation and amortization

 

 

10,336

 

 

 

9,926

Total operating costs and expenses

 

 

67,070

 

 

 

66,055

 

 

 

 

 

 

 

 

Operating income

 

 

5,690

 

 

 

2,891

 

 

 

 

 

 

 

 

Other income, net

 

 

853

 

 

 

250

 

 

 

 

 

 

 

 

Income before income tax provision

 

 

6,543

 

 

 

3,141

Income tax provision

 

 

1,316

 

 

 

518

Net income

 

$

5,227

 

 

$

2,623

 

 

 

 

 

 

 

 

Net income per share:

 

 

 

 

 

 

 

Basic

 

$

0.17

 

 

$

0.09

Diluted

 

$

0.17

 

 

$

0.09

 

 

 

 

 

 

 

 

Weighted average shares of common stock outstanding:

 

 

 

 

 

 

 

Basic

 

 

30,313

 

 

 

30,591

Diluted

 

 

30,418

 

 

 

30,659

Dividends declared per share

 

$

0.028

 

 

$

0.025

HEALTHSTREAM, INC.

Condensed Consolidated Balance Sheets

(In thousands)

(Unaudited)

 

 

 

 

 

 

 

 

 

March 31,

 

 

December 31,

 

 

 

2024

 

 

2023

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

52,407

 

 

$

40,333

 

Marketable securities

 

 

31,265

 

 

 

30,800

 

Accounts and unbilled receivables, net

 

 

44,054

 

 

 

38,446

 

Prepaid and other current assets

 

 

19,663

 

 

 

20,631

 

Total current assets

 

 

147,389

 

 

 

130,210

 

 

 

 

 

 

 

 

 

 

Capitalized software development, net

 

 

41,118

 

 

 

40,643

 

Property and equipment, net

 

 

12,537

 

 

 

13,005

 

Operating lease right of use assets, net

 

 

19,483

 

 

 

20,114

 

Goodwill and intangible assets, net

 

 

255,522

 

 

 

259,410

 

Deferred commissions

 

 

30,671

 

 

 

31,700

 

Other assets

 

 

4,885

 

 

 

4,860

 

Total assets

 

$

511,605

 

 

$

499,942

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable, accrued and other liabilities

 

$

27,802

 

 

$

34,738

 

Deferred revenue

 

 

98,268

 

 

 

83,623

 

Total current liabilities

 

 

126,070

 

 

 

118,361

 

Deferred tax liabilities

 

 

16,868

 

 

 

16,132

 

Deferred revenue, noncurrent

 

 

2,076

 

 

 

2,169

 

Operating lease liability, noncurrent

 

 

19,484

 

 

 

20,247

 

Other long-term liabilities

 

 

2,253

 

 

 

2,281

 

Total liabilities

 

 

166,751

 

 

 

159,190

 

 

 

 

 

 

 

 

 

 

Shareholders' equity:

 

 

 

 

 

 

 

 

Common stock

 

 

249,280

 

 

 

249,075

 

Accumulated other comprehensive loss

 

 

(1,172

)

 

 

(691

)

Retained earnings

 

 

96,746

 

 

 

92,368

 

Total shareholders' equity

 

 

344,854

 

 

 

340,752

 

Total liabilities and shareholders' equity

 

$

511,605

 

 

$

499,942

 

 

 

HEALTHSTREAM, INC.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

 

 

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

March 31,

 

 

 

2024

 

 

2023

 

Operating activities:
Net income$

5,227

$

2,623

Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization

10,336

9,926

Stock-based compensation

1,060

945

Amortization of deferred commissions

2,957

2,712

Deferred income taxes

771

800

Provision for credit losses

174

209

Loss on equity method investments

31

127

Other

(346

)

(85

)

Changes in assets and liabilities:
Accounts and unbilled receivables

(5,782

)

(4,787

)

Prepaid and other assets

(1,783

)

(2,750

)

Accounts payable, accrued, and other liabilities

(6,259

)

(3,683

)

Deferred revenue

14,552

14,504

Net cash provided by operating activities

20,938

20,541

 
Investing activities:
Business combinations, net of cash acquired

(6,621

)

Changes in marketable securities

(124

)

(1,850

)

Proceeds from sale of non-marketable equity investments

765

Purchases of property and equipment

(742

)

(879

)

Payments associated with capitalized software development

(7,019

)

(7,566

)

Net cash used in investing activities

(7,120

)

(16,916

)

 
Financing activities:
Taxes paid related to net settlement of equity awards

(855

)

(791

)

Payment of cash dividends

(849

)

Net cash used in financing activities

(1,704

)

(791

)

 
Effect of exchange rate changes on cash and cash equivalents

(40

)

(21

)

Net increase in cash and cash equivalents

12,074

2,813

Cash and cash equivalents at beginning of period

40,333

46,023

Cash and cash equivalents at end of period$

52,407

$

48,836

 

 

 

Reconciliation of GAAP to Non-GAAP Financial Measures(1)

Operating Results Summary

(In thousands)

(Unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2024

 

 

2023

 

Net income

 

$

5,227

 

 

$

2,623

 

Deferred revenue write-down

 

 

 

 

 

50

 

Interest income

 

 

(904

)

 

 

(363

)

Interest expense

 

 

24

 

 

 

33

 

Income tax provision

 

 

1,316

 

 

 

518

 

Stock-based compensation expense

 

 

1,060

 

 

 

945

 

Depreciation and amortization

 

 

10,336

 

 

 

9,926

 

Adjusted EBITDA

 

$

17,059

 

 

$

13,732

 

(1) This press release presents adjusted EBITDA, which is a non-GAAP financial measure used by management in analyzing its financial results and ongoing operational performance.

Reconciliation of GAAP to Non-GAAP Financial Measures

Financial Outlook for 2024

(In thousands)

(Unaudited)

 

 

 

Low

 

 

High

 

Net income

 

$

14,500

 

 

$

16,500

 

Interest income

 

 

(2,400

)

 

 

(2,600

)

Interest expense

 

 

100

 

 

 

100

 

Income tax provision

 

 

5,200

 

 

 

5,800

 

Stock-based compensation expense

 

 

4,800

 

 

 

5,000

 

Depreciation and amortization

 

 

42,300

 

 

 

42,700

 

Adjusted EBITDA

 

$

64,500

 

 

$

67,500

 

This press release includes certain forward-looking statements (statements other than solely with respect to historical fact), including statements regarding expectations for financial performance for 2024 and our quarterly dividend policy, that involve risks and uncertainties regarding HealthStream. These statements are based upon management's beliefs, as well as assumptions made by and data currently available to management. This information has been, or in the future may be, included in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions that forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements to be materially different from future results, performance, or achievements expressed or implied by the forward-looking statements, including as a result of negative economic conditions, ongoing inflationary and recessionary pressures, geopolitical instability (including as the result of the Russia/Ukraine conflict, the conflict in the Middle East, and the potential expansion of such conflicts), legal requirements and contractual restrictions which may affect continuation of our quarterly cash dividend policy and the declaration and/or payment of dividends thereunder, which may be modified, suspended, or canceled in any manner and at any time that our Board may deem necessary or appropriate, as well as risks referenced in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed on February 26, 2024, and in the Company's other filings with the Securities and Exchange Commission from time to time. Consequently, such forward-looking information should not be regarded as a representation or warranty or statement by the Company that such projections will be realized. Many of the factors that will determine the Company's future results are beyond the ability of the Company to control or predict. Readers should not place undue reliance on forward-looking statements, which reflect management's views only as of the date hereof. The Company undertakes no obligation to update or revise any such forward-looking statements.

Scott A. Roberts
Chief Financial Officer
(615) 301-3182
ir@healthstream.com

Media:
Mollie Condra, Ph.D.
Vice President,
Investor Relations &
Communications
(615) 301-3237
mollie.condra@healthstream.com

Source: HealthStream, Inc.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.